Objectives: The aim of this study was to determine the anaerobic spectrum of activity of REP3123, a novel diaryldiamine that inhibits bacterial methionyl-tRNA synthetases in Gram-positive bacteria.
Introduction
Clostridium difficile infection (CDI) has increased in prevalence and severity during the last decade, resulting in higher case fatality, mortality and increased colectomy rates. 1 Since current C. difficile therapy with metronidazole and even vancomycin continues to have only moderate efficacy and unacceptable relapse rates, 1,2 new drugs are being sought, particularly narrowspectrum agents. Narrow-spectrum agents would be less likely to disrupt the ecological balance of the indigenous intestinal flora and destroy the colonization resistance provided by the broad array of intestinal anaerobes present in the gut. 3 -7 REP3123 is a novel diaryldiamine derived from REP8839 8 that predominantly inhibits bacterial methionyl-tRNA synthetase (MetRS) enzymes in Gram-positive bacteria. It has excellent in vitro activity against C. difficile and also inhibits toxin production, as well as sporulation by C. difficile, as shown in the companion manuscripts by Critchley et al. 9 and Ochsner et al.
10
REP3123 is under evaluation as an oral, non-absorbable agent for the treatment of CDI. It is primarily bacteriostatic against C. difficile and, similar to vancomycin, reduces cfu counts by 2log 10 after 24 h (U. Ochsner, Replidyne, Inc., personal communication).
To further investigate the potential of REP3123, we determined its in vitro activity compared with that of vancomycin, metronidazole, clindamycin, amoxicillin/clavulanate and moxifloxacin against 50 recent clinical isolates of C. difficile from patients diagnosed with CDI and 223 other intestinal normal flora anaerobes. The C. difficile isolates were from several different geographic locations and time periods, and included seven REA type BI/NAP1/027 strains with known resistance to moxifloxacin.
Materials and methods
The organisms were recovered from clinical specimens and stored at 2708C in 20% skimmed milk. MICs of REP3123, metronidazole, vancomycin, amoxicillin/clavulanate and clindamycin were determined. Moxifloxacin MICs were determined for some of the C. difficile isolates as well. The antimicrobial agents were obtained as follows: REP3123, Replidyne, Inc., Louisville, CO, USA; metronidazole and vancomycin, Sigma-Aldridge, St Louis, MO, USA; clindamycin, Voigt Global Distribution, Lawrence, KS, USA; amoxicillin/ clavulanate, GlaxoSmithKline, Research Triangle Park, NC, USA; and moxifloxacin, IHMA, Inc., Schaumberg, IL, USA. REP3123 was tested at concentrations of 32 to 0.03 mg/L. Higher concentrations were not tested due to solubility factors. Susceptibilities were determined by the agar dilution method according to procedures in the CLSI document M11-A7.
11 Serial 2-fold dilutions of the drugs were prepared and added to molten agar to prepare the plates. REP3123 was dissolved and diluted in dimethyl sulphoxide (DMSO) and added to the molten agar at a dilution of 1:100.
Drug-free plates with 1% DMSO were included as growth controls. DMSO at a concentration of 1% does not affect bacterial growth.
11
Quality control strains included C. difficile ATCC 700057 and Staphylococcus aureus ATCC 29213.
Organisms were taken from the freezer and transferred at least twice to ensure purity and good growth. On the day of testing, colonies from 48 h plates were suspended in Brucella broth to Continued obtain a turbidity equivalent to that of a 0.5 McFarland standard and applied to the plates with a Steers replicator for a final inoculum of 10 5 cfu/spot. After incubation at 378C for 48 h in an anaerobic chamber, the plates were examined and MICs determined. The MIC was the lowest concentration of the antibiotic that resulted in a marked reduction of growth compared with the growth control.
Results
The results are presented in Table 1 . All strains of C. difficile were inhibited by 0.5-1 mg/L REP3123, including those resistant to moxifloxacin and clindamycin. While the drug showed good activity against several other clostridia including Clostridium perfringens, the Clostridium clostridioforme group and Clostridium paraputrificum, the MICs for Clostridium ramosum, a major component of gut flora, were 16 -32 mg/L. There was also poor activity against the bifidobacteria (MICs. 32 mg/L), an important finding since these are part of the normal flora anaerobes in the gut and play an important role in maintaining the colonization resistance barrier. Similarly, the lactobacilli of the Lactobacillus casei -rhamnosus -plantarum group were not inhibited by 32 mg/L REP3123. While the Actinomyces species do not constitute a major part of the intestinal flora, they also were not inhibited.
Among the Gram-negative species, all members of the Bacteroides fragilis group and Prevotella species had MICs .32 mg/L. The Porphyromonas asaccharolytica strains showed a bimodal distribution of MICs ranging from 0.25 to .32 mg/L, which is similar to the decreased inhibition seen with vancomycin. The intestinal strains of fusobacteria, Fusobacterium mortiferum and Fusobacterium varium were susceptible, with MICs ranging from 0.06 to 1 mg/L. While most of the anaerobic cocci were susceptible, the Anaerococcus species and Finegoldia magna showed higher MICs ranging from 1 to 8 mg/L.
Discussion
Previous studies have evaluated the in vitro activity of other agents, which appear to have excellent activity against C. difficile; however, clinical failures and relapses are a frequent occurrence with all standard therapies. 2, 3, 12, 13 While the cause of failure remains unknown, some have suggested that C. difficile forms spores in the gut, which are resistant to antimicrobial agents and thus persist, but later germinate to cause recurrence of clinical disease. Inhibition of sporulation has the potential of not only preventing recurrence, but also decreasing contamination of the environment with spores. 10 Moreover, the decreased toxin production may further mitigate the symptoms associated with this disease.
12
Our MIC results for Gram-negative species are similar to those reported by Credito et al. 13 in a study of OPT-80, a novel macrocycle antibiotic, against C. difficile and other anaerobes. Similar to the activity of REP3123, they also reported nonspeciated strains of lactobacilli, bifidobacteria and Actinomyces to be resistant to OPT-80. They did not report MICs separately for C. ramosum, which we found to be resistant to the highest concentrations of REP3123 tested. MICs of vancomycin and metronidazole were within one dilution of those in our study. Another report by Hecht et al.
14 found MIC 90 s of vancomycin to be the same, but metronidazole MIC 90 at two dilutions lower than those in the present study. The reason for this is unknown. The increase in moxifloxacin resistance that we detected was also present in their study. 
, C. sporogenes (1), C. subterminale (1) and C. symbiosum (4). c Collinsella aerofaciens (3), Eubacterium biforme (1), E. contortum (1), E. cylindroides (1), E. limosum (6), Mogibacterium timidum (1) and Prevotella bivia (2), P. buccae (2), P. denticola (1), P. intermedia/nigrescens (3), P. loeschii (2), P. melaninogenica (3), P. oralis (1) and P. oris (1).
The reason for the relative selectivity of REP3123 activity against C. difficile found in our study is not known. REP3123 targets the MetRS enzyme in Gram-positive organisms, essential for protein biosynthesis, which is modified in Gram-negative organisms, making them resistant. However, MetRS enzymes in other Gram-positive anaerobes included in our study have not been examined, but may have slight modifications in their structure, accounting for the decreased susceptibly to REP3123. 9 Additional work will need to be done to further elucidate this finding.
While dosing concentrations with corresponding faecal levels have not yet been studied in humans, they should be such that the levels achieved in the gut will maintain the selectivity of this agent in vivo.
Conclusions
Coupled with the favourable spectrum of activity against intestinal normal flora anaerobes, REP3123 shows promise as a candidate for animal and clinical trials for CDI treatment.
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